AU2003229437A1 - Use of lanthanum for the treatment of hypercalcemia and bone metastasis - Google Patents

Use of lanthanum for the treatment of hypercalcemia and bone metastasis

Info

Publication number
AU2003229437A1
AU2003229437A1 AU2003229437A AU2003229437A AU2003229437A1 AU 2003229437 A1 AU2003229437 A1 AU 2003229437A1 AU 2003229437 A AU2003229437 A AU 2003229437A AU 2003229437 A AU2003229437 A AU 2003229437A AU 2003229437 A1 AU2003229437 A1 AU 2003229437A1
Authority
AU
Australia
Prior art keywords
hypercalcemia
lanthanum
treatment
bone metastasis
metastasis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003229437A
Other versions
AU2003229437A8 (en
Inventor
Isobel Webster
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire Holdings AG
Original Assignee
Shire Holdings AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Holdings AG filed Critical Shire Holdings AG
Publication of AU2003229437A8 publication Critical patent/AU2003229437A8/en
Publication of AU2003229437A1 publication Critical patent/AU2003229437A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2003229437A 2002-05-08 2003-05-08 Use of lanthanum for the treatment of hypercalcemia and bone metastasis Abandoned AU2003229437A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37840102P 2002-05-08 2002-05-08
US60/378,401 2002-05-08
PCT/CA2003/000684 WO2003094933A2 (en) 2002-05-08 2003-05-08 Use of lanthanum for the treatment of hypercalcemia and bone metastasis

Publications (2)

Publication Number Publication Date
AU2003229437A8 AU2003229437A8 (en) 2003-11-11
AU2003229437A1 true AU2003229437A1 (en) 2003-11-11

Family

ID=29420395

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003229437A Abandoned AU2003229437A1 (en) 2002-05-08 2003-05-08 Use of lanthanum for the treatment of hypercalcemia and bone metastasis

Country Status (2)

Country Link
AU (1) AU2003229437A1 (en)
WO (1) WO2003094933A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060083791A1 (en) 2002-05-24 2006-04-20 Moerck Rudi E Rare earth metal compounds methods of making, and methods of using the same
US20040161474A1 (en) 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
EA200970709A1 (en) * 2003-08-26 2010-04-30 Шир Холдингз Аг PHARMACEUTICAL COMPOSITION CONTAINING LANTHANE COMPOUNDS
US7381428B2 (en) 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
CN101018555A (en) * 2004-07-27 2007-08-15 夏尔制药公司 Method of treating hyperphosphataemia using lanthanum hydroxycarbonate
CA2583548A1 (en) * 2004-10-15 2006-04-27 Altairnano, Inc. Phosphate binder with reduced pill burden
US7862836B2 (en) * 2005-04-12 2011-01-04 Biolink Life Sciences, Inc. Phosphorus binder for treatment of kidney disease
JP2009504779A (en) * 2005-08-17 2009-02-05 アルテアナノ インコーポレイテッド Treatment of chronic renal failure and other illnesses in livestock: compositions and methods
WO2011143475A1 (en) 2010-05-12 2011-11-17 Spectrum Pharmaceuticals, Inc. Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use
CN103127041A (en) * 2012-02-23 2013-06-05 南京卡文迪许生物工程技术有限公司 Medicinal composition with lanthanum acetate, preparation method and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506126D0 (en) * 1995-03-25 1995-05-10 Johnson Matthey Plc Pharmaceutical composition and method
GB0015745D0 (en) * 2000-06-27 2000-08-16 Shire Holdings Ag Treatment of bone diseases

Also Published As

Publication number Publication date
AU2003229437A8 (en) 2003-11-11
WO2003094933A3 (en) 2004-04-01
WO2003094933A2 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
AU2003228445A1 (en) Tissue composites and uses thereof
EP1555957A4 (en) Sealants for skin and other tissues
IL166448A0 (en) Thiomolybdate analogues and uses thereof
EP1539941A4 (en) Adzymes and uses thereof
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
EP1539931A4 (en) Differentiation modulating agents and uses therefor
PL358848A1 (en) Bone treatment material
AU2003229437A1 (en) Use of lanthanum for the treatment of hypercalcemia and bone metastasis
ZA200500921B (en) Thiomolybdate analogues and uses thereof
AU2003258869A1 (en) Integrated beauty care apparatus
AU2003231827A8 (en) Pseudo-tissues and uses thereof
AU2003268939A1 (en) Bisphosphonates for the treatment of antheroscleorosis and devices comprising them
AU2003293500A1 (en) Lactoferrin in the reduction of pain
AU2003259689A1 (en) 3-imino-2-indolones for the treatment of depression and/or anxiety
AU2003224348A1 (en) Bone densitometry and mammography
AU2003273817A8 (en) Increasing of the resorption of substances via skin and mucous membranes
AU2003216442A8 (en) Enkurin and uses thereof
AU2003228397A1 (en) HAUSP-p53 INTERACTION AND USES THEREOF
AU2003255232A1 (en) Antigiardial agents and use thereof
GB0229986D0 (en) Treatment of materials
AU2003245211A1 (en) Treatment of osteoporosis
GB0221955D0 (en) Compounds and their medical uses
GB0221954D0 (en) Compounds and their medical uses
AU2002313005B2 (en) Use of glycoprotein for the treatment and re-epithelisation of wounds
AU2003298547A1 (en) 2,4,6-triaminopyrimidines for the treatment of depression and/or anxiety

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
TH Corrigenda

Free format text: IN VOL 18, NO 2, PAGE(S) 584 UNDER THE HEADING APPLICATIONS OPI - NAME INDEX UNDER THE NAME SHIRE HOLDING AG , APPLICATION NO. 2003229437, UNDER INID (43) CORRECT THE PUBLICATION DATE TO READ 24.11.2003